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Table 1
Sample size estimated for efﬁcacy trials with different treatment effects, trial
lengths, and biomarker metrics. Trials included visits of 3, 6, 12 or 24 months up to
stated trial length, except 6 & 12 month which is a 12 month trial with no 3 month
visit. Averaged regions were all regions, or 4 regions with most positive (Top 4) or
most negative (Bottom 4) change
Avg magnitude
of change inAverage change in
Treatment Trail length All Top 4 Bottom 4 All Top 4
Partial stop 24 Months >50000 256 326 95 109
12 Months 9788 254 450 103 106
6 & 12 Months 8958 204 415 87 102
6 Months 9038 310 698 138 143
2% Growth 24 Months 76 927 67 281 212
12 Months 259 10765 107 158 140
6 & 12 Months 195 21745 96 144 140
6 Months 828 1696 204 171 161
5% Growth 24 Months 13 32 21 58 1419
12 Months 35 197 35 15084 1084
6 & 12 Months 27 124 31 1123 2410
6 Months 96 1590 72 647 350
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Purpose: The choice of an efﬁcacy biomarker for cartilage change in a
clinical trial for structural treatment of osteoarthritis depends on
expected treatment effects, disease progression patterns, and trial
length. Previous work has shown that local increases and decreases in
cartilage thickness in study participants may occur over short periods of
time. Presumably treatment would minimize both thinning and thick-
ening aspects of disease progression, but could also lead to localized or
global cartilage growth. Hence simple averaging of cartilage loss across
joint compartments or cartilage plates may not efﬁciently capture the
complexity of thickness change, likely to be seen in shorter clinical
trials. This study examines different metrics of cartilage thickness
change for clinical trials under different trial lengths and treatment
effects.
Methods: Estimations of sample size (N) for clinical trials were based
on differences in cartilage thickness change observed in coronal MR
images (3 Tesla) of 145 women (71 with medial radiographic osteo-
arthritis (ROA), 74 with no symptoms or ROA) at baseline, 3, 6, 12 and 24
months of an observational trial. Femorotibial cartilage thickness was
determined across 5 tibial and 3 femoral subregions in each (medial/
lateral) compartment. Sample size per arm (treatment, control, two-
sample t-test) was used to measure the efﬁciency of different clinical
trial and biomarker choices. Three treatment effects were considered:
disease progression, the mean difference in change between ROA and
asymptomatic subjects, is reduced by 50%, and global growth of 2% or
5%. Two trial parameters were explored: trial length (3, 6, 12 or 24
months), and whether a single or multiple visits were included in the
statistical analysis. All biomarkers considered were univariate, i.e., they
summarized change frommultiple regions and visits into a single value
per subject. Other biomarker parameters examined: use of thickness
change (c) or magnitude (absolute value) of change (jcj); choice of
regions (all, medial, central or external (C/E) medial regions or C/E
medial regions individually or choice dependent on magnitude of
change); methods of summarizing over regions and visits (average,
maximum or minimum).
Results: Multi-visit metrics had smaller N than single visit metrics. A 3
month visit was not informative; N for 3 month trials were large, N >
325 and was typically more than twice as large as needed at 6 months;
and including a 3 month visit did not reduce N in multi-visit metrics.
Biomarkers averaging all or just medial regions had smaller N than
individual regions or the average of the C/E medial regions. Table 1
reports results for biomarkers that consistently had small N across
visits for at least one of the treatment effects. Averages of the regions
with the most positive or most negative changes were often the most
efﬁcient biomarkers, but how these changes were included depended
on treatment scenario. When the treatment slowed cartilage disease
progression, trials using jcj had smaller sample sizes (87 < N < 166)
than using thickness change, c (N > 168) regardless of trial length. On
the other hand, with global 5% growth, biomarkers based on c were
estimated to have much smaller sample sizes (N< 100) than when
based on jcj (N > 300), except when average jcj over all regions in 24
month trials (N ¼ 58). The most efﬁcient change biomarkers under 5%
global growth were the average of all regions and, perhaps surpris-
ingly, the average of the 4 most negative changes. Biomarkers based on
c and jcj are nearly comparable for 2% growth treatment scenario. The
average of regions with the most negative changes, c, (67 < N < 204)
was more efﬁcient than using average of regions with largest magni-
tude jcj (140 < N < 212), but not by much and was slightly worse for a
6 month trial.
Conclusions: Efﬁcacy trials for cartilage change of 6 or 12 months may
achieve reasonable treatment goals with sample sizes < 200/arm.
Generally the most efﬁcient cartilage thickness biomarkers were those
that measured the largest negative changes or the largest changes in
absolute value, but the choice between these biomarkers depended on
trial length and expected treatment beneﬁt.108
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Purpose: Aggrecan, the main proteoglycan in cartilage extracellular
matrix, is proteolysed in joint injuries and in osteoarthritis. The main
proteases digesting aggrecan are the matrix metalloproteases (MMPs)
and aggrecanases, but aggrecan can also be cleaved by calpains and
cathepsins. The question that we asked was: is there a speciﬁc pro-
teolytic aggrecan fragmentation pattern (aggrecan fragmentology)
which depends on disease and/or disease development?
Methods: Synovial ﬂuid (SF) from subject groups was pooled: knee
healthy reference (n ¼ 10; age range ¼ 19-58 years), adult knee injuries
(n¼ 64;mean age¼ 33 years), juvenile knee injuries (n¼ 9; age range¼
12-15 years), osteoarthritis (OA, n ¼ 47; mean age ¼ 48 years), and
juvenile idiopathic arthritis (JIA, n ¼ 120; age range ¼ 13-19 years). The
total sulphated glycosaminoglycan was analysed in the SF-pools by
Alcian blue precipitation, and the values were converted to total
aggrecan using an assumption that the aggrecanMw¼ 1500 000 g/mol
and that 75% of the Mw comes from the glycosaminoglycan’s. Aggrecan
fragments were puriﬁed from the SF-pools using CsCl density gradient
centrifugation collecting the SF-D1 fractions. Puriﬁed calf aggrecan
(A1D1 fraction from CsCl density gradient centrifugation) was used as
full length G1-G3 standards for Western blot quantiﬁcations, and total
degradation of puriﬁed human aggrecan (A1D1 fraction) was used to
make ARGS (aggrecanase-1 digest), FFGV (MMP-3 digest) and PGVA (m-
calpain digest) standards. The standards and the SF-D1 samples were
deglycosylated and visualized by Western blot using anti-aggrecan
neoepitope antibodies ARGS, FFGV, PGVA and an anti-aggrecan G3
antibody. Total amount (mean pmol) of ARGS, FFGV, G1-G3, inter
globular domain (IGD)-PGVA and chondroitin sulfate region 2 (CS2)-G3
fragments was calculated (using Western blot and standards) for each
subject group, and the proportion of fragments (% of aggrecan) was
calculated in relation to the total amount of fragments detected in each
group.
Results: The total amount aggrecan detected in the SF pools was
approximately 2-3 higher in the knee injury groups (adult and juvenile
injury) and in the OA group (101 – 129 pmol/ml) compared to the knee
healthy reference and the JIA groups (44 and 45 pmol/ml). The dis-
tribution of full length aggrecan (G1-G3) and of aggrecanase (ARGS and
CS-G3), MMP (FFGV) and calpain (IGD-PGVA) generated fragments was
different between patient groups (Fig. 1). Of the total amount of frag-
ments detected, calpain generated PGVA fragments was low in the
different patients groups, although the reference group contained 7%
PGVA fragments. The adult and juvenile injury groups and the OA group
